Medicamen Organics Ltd. · NSE:MEDIORG
Medicamen Organics — H1 FY25 Earnings Presentation
45 slides from Medicamen Organics's earnings presentation, Nov 23, 2024
Slide 1: Regulation 30 announcement letter to NSE
November 23, 2024 To, National Stock Exchange of India Limited Listing & Compliance Department Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra Mumbai - 400051, India. Company Symbol : MEDIORG Company ISIN : INE0PE401018 Dear Sir/Madam, Subject: Announcement under Regul
Slide 2: H1 FY25 Investor Presentation
MEDICAMEN ORGANICS LIMITED H1 FY25 Investor Presentation Investor Presentation 1
Slide 3: Disclaimer
Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by Medicamen Organics Limited (“MOL”, The Company) solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities and sha
Slide 4: H1 FY25 Financial Highlights
H1 FY25 Financial Highlights
Slide 5: H1 FY25 Key Financial Highlights
H1 FY25 Key Financial Highlights Total Income EBITDA Net Profit EBITDA Margin Net Profit Margin 277 21% 1,686 241 16% 1,133 12% 151 136 9% H1 FY24 H1 FY25 H1 FY24 H1 FY25 H1 FY24 H1 FY25 All Figures In ₹ Lakhs & Margin in % Investor Presentation 4
Slide 6: H1 FY25 Profit & Loss Statement
H1 FY25 Profit & Loss Statement In ₹ Lakhs Particulars H1 FY24 H1 FY25 Y-O-Y Revenues 1,132 1,661 Other Income 1 25 Total Income 1,133 1,686 49% Raw Material Expenses 657 1,145 Employee Costs 170 176 Other Expenses 64 88 Total Expenditure 892 1,408 EBITDA 241 277 15% Finance Costs 29 22 Depreciation
Slide 7: Company Overview
Company Overview
Slide 8: Medicamen Organics Limited Expanding Horizons In Pharma Market
Medicamen Organics Limited Expanding Horizons In Pharma Market Medicamen Organics Limited specializes in the development, manufacturing, and distribution of pharmaceutical products which includes tablets, capsules, syrups and ointments. The company Provides contract and third-party manufacturing ser
Slide 9: Vision & Mission
Vision & Mission Mission Vision To pioneer advancements in medicine by To create a healthier world where leveraging cutting-edge research and technology. innovative medications positively The company aspire to be a global leader in impact the lives of patients and pharmaceutical innovation, setting
Slide 10: Key Facts & Figures
Key Facts & Figures 25+ 5 170+ 80+ Years Of Experience Product Category Products For Export Domestic Products ISO 9001:2015 2 21,600 112+ Annual Installed Certified Company Manufacturing Team Size Capacity Facilities (in Lakh tablets) FY24 (Audited) Revenue EBITDA PAT ₹ 2,527 Lakhs ₹ 476 Lakhs ₹ 262
Slide 11: Key Milestones In MOL's Journey
Key Milestones In MOL’s Journey • Reconstructed Unit II, creating a 20,000 sq. ft. area for producing • The company got • Incorporated as various pharmaceutical products and "Panchdeep listed on NSE received the necessary 2017 Emerge Platform Pharmaceuticals manufacturing licenses and WHO Limited" a
Slide 12: A Legacy Of Excellence
A Legacy Of Excellence Export Award Pharmexcil Award for Commerce & Industry Presented By: Hon'ble Shri Pranab Mukherjee, Former Category: "Fast Emerging President of India Company” Year: 2015 Year: 2008-09 Investor Presentation 11
Slide 13: Business Overview
Business Overview
Slide 14: Contract Manufacturing: B2B Partnerships
Contract Manufacturing: B2B Partnerships MOL Specializes In B2B Contract Manufacturing, Partnering With Third-party Pharmaceutical Companies Who Market & Sell Products To Companies Involved In Both Ethical Marketing & Generics In Domestic & International Markets. Key Highlights Market Presence Owner
Slide 15: Contract Manufacturing: Government Contract
Contract Manufacturing: Government Contract Active Participation In Government Tenders To Supply Products To Various Government Entities, Including Hospitals, Departments, Psus, & Armed Forces. Advantages The Company Have Supplied To 11 Government Institutions Diverse Revenue Streams Mix of B2B part
Slide 16: From Health To Wellness: Product Categories
From Health To Wellness: Product Categories Capsules: Targeted Treatments for Diverse Tablets: Health Needs MOL manufactures a variety of Focused on developing iron capsule formulations, tailored to supplements to address common address specific health nutritional deficiencies conditions Rabeprazole
Slide 17: From Health To Wellness: Product Categories
From Health To Wellness: Product Categories Ointments and External Dry Powder Sachets: Preparations: Convenient Dosage Form Specialized Topical Solutions Company’s portfolio includes a Innovative sachets designed for wide range of topical antifungal easy administration and and antibacterial formulat
Slide 18: From Health To Wellness: Product Categories
From Health To Wellness: Product Categories Syrups/Suspensions: Diverse Range of Oral Liquids MOL excels in developing and manufacturing a variety of oral liquid formulations, designed for different therapeutic needs Cough Syrups A comprehensive range to address various types of cough and respirator
Slide 19: Strategic Facilities: Combining Quality & Flexibility
Strategic Facilities: Combining Quality & Flexibility The Company operates two advanced manufacturing facilities strategically located in Haridwar, designed to ensure the efficient production of high-quality pharmaceutical products. Company’s facilities are equipped with cutting-edge machinery and r
Slide 20: Strategic Facilities: Combining Quality & Flexibility
Strategic Facilities: Combining Quality & Flexibility Products Unit 1 Unit 2 Tablets (In Lakh) 10,800 10,800 Suspension (In Litre) 9,36,000 Capsules (In Lakh) 780 Ointment (In Kg) 93,600 Dry Powder Sachets (In No) 37,44,000 Investor Presentation 19
Slide 21: Broadening Global Presence: Current & Future Markets
Broadening Global Presence: Current & Future Markets Current International Presence Congo Myanmar Benin Mozambique Cameg Burundi Togo Kyrgyzstan Senegal Kenya Burkina Faso Philippines Future Plans Of Geographical Expansion Mauritius Tanzania Rwanda Cameroon Sierra Leone Ivory Coast Nepal Colombia Ch
Slide 22: Strategic Partnerships: Building Success Together
Strategic Partnerships: Building Success Together In FY24 The Top 10 Customers Contributed Around 79% Of The Total Sales Investor Presentation 21
Slide 23: Growth Strategies
Growth Strategies
Slide 24: Strategic Growth & Expansion Initiatives
Strategic Growth & Expansion Initiatives The company is transitioning from its As part of its global expansion strategy, MOL plans traditional export model to marketing to enter the selected African countries such as its own brands in international Rwanda, Francophone countries, Tanzania etc. with m
Slide 25: Expansion Into Francophone Africa
Expansion Into Francophone Africa Francophone Africa Is An Attractive Region For Expansion Due To Rising Demand For Pharmaceuticals, Driven By Population Growth. The AfCFTA, Universal Healthcare Initiatives, & Regional Efforts Like The West African Common Market Also Enhance Access & Boost Pharmaceu
Slide 26: Strategic Investment: Expanding Horizons in Rwanda
Strategic Investment: Expanding Horizons in Rwanda MOL Selected Rwanda For Its Expansion Due To Strategic Location For Piloting Operations In East Africa, Safe Business Environment And The Country's High Accounting Standards. Rwanda's Cashless Economy Ensures Secure Transactions, Allowing For Low In
Slide 27: Management Overview
Management Overview
Slide 28: Experienced Promoters
Experienced Promoters Mr. Bal Kishan Gupta Mr. Ashutosh Gupta Chairman cum Managing Director Whole Time Director 40+ Years Of Experience 19+ Years Of Experience Mr. Bal Kishan Gupta, a seasoned Ashutosh Gupta, aged 43, holds a degree in professional with extensive experience in the Business Administ
Slide 29: Board Of Directors
Board Of Directors Mr. Shailesh Gaur Mrs. Sneh Gaur Mr. Sachin Gupta Mr. Rajinder Kumar Gupta Mr. Rakesh Kumar Executive Director Director Independent Director Independent Director Independent Director 33+ Years Of Experience 08+ years of experience 20+ years of experience 30+ years of experience 25
Slide 30: Industry Overview
Industry Overview
Slide 31: Indian Pharmaceutical Industry
Indian Pharmaceutical Industry India ranks 3rd The country has an According to Major Segments of the Pharmaceutical is one of worldwide for established domestic Government data, the Pharmaceutical the top ten attractive pharmaceutical pharmaceutical Indian pharmaceutical Industry are Generic sectors
Slide 32: Indian Pharmaceutical Export Market
Indian Pharmaceutical Export Market Contract Research & Manufacturing Services (CRAMS) Contract research and manufacturing services is one of the fastest growing segments in the pharmaceutical and biotechnology industry. The pharmaceutical market uses outsourcing services from providers in the form
Slide 33: Industry Growth Drivers
Industry Growth Drivers IPR & Innovation Global Regulatory Approvals Export Strength Product innovation and strong intellectual International plant approvals from stringent Significant exports to regulated markets property rights through patents and authorities like US FDA, EMA, and PMDA, (USA, Euro
Slide 34: Financial Overview
Financial Overview
Slide 35: Key Financial Highlights
Key Financial Highlights Total Income EBITDA PAT EBITDA Margin PAT Margin 19% 476 2,529 12% 10% 2,296 269 262 7% 5% 2,118 138 125 0.5% 8 FY22 FY23 FY24 FY22 FY23 FY24 FY22 FY23 FY24 All Figures In ₹ Lakhs & Margin in % Investor Presentation 34
Slide 36: Profit & Loss Statement
Profit & Loss Statement In ₹ Lakhs Particulars FY22 FY23 FY24 Revenues 2,098 2,215 2,527 Other Income 21 82 2 Total Income 2,119 2,296 2,529 Raw Material Expenses 1,566 1,580 1,580 Employee Costs 287 317 335 Other Expenses 128 132 138 Total Expenditure 1,981 2,028 2,053 EBITDA 138 269 476 Finance Co
Slide 37: Balance Sheet
Balance Sheet In ₹ Lakhs Equities & Liabilities FY22 FY23 FY24 Assets FY22 FY23 FY24 Equity 600 600 860 Non Current Assets Reserves 147 269 666 Fixed Assets 1,033 982 1,050 Net Worth 747 869 1,526 Non Current Investments 0 0 0 Non Current Liabilities Other Non Current Financial Assets 24 0 33 Long T
Slide 38: Cash Flow Statement
Cash Flow Statement In ₹ Lakhs Particulars FY22 FY23 FY24 Cashflow From Operations -9 -62 -261 Cashflow From Investments -59 -28 -139 Cashflow From Financing 23 99 401 Net Cash Flow -46 9 1 Opening Cash & Cash Equivalent 90 45 54 Closing Cash & Cash Equivalent 45 54 55 Investor Presentation 37
Slide 39: Consolidated Key Ratios
Consolidated Key Ratios In % In Times In ₹ ROE Debt To Equity Book Value 1.37 1.36 17.74 21.91 14.49 13.35 15.50 0.83 1.06 FY22 FY23 FY24 FY22 FY23 FY24 FY22 FY23 FY24 In % In Times In ₹ ROCE Interest Coverage EPS 3.47 14.46 6.23 9.21 2.09 3.13 3.51 1.54 0.13 FY22 FY23 FY24 FY22 FY23 FY24 FY22 FY23
Slide 40: Revenue Breakdown: Government Contracts & Contract Manufacturing
Revenue Breakdown: Government Contracts & Contract Manufacturing In % FY22 FY23 FY24 3% 16% 1 1 84% 97% Government Contract Contract Manufacturing In ₹ Lakhs Particulars FY22 FY23 FY24 Government Contract 72 361 57 Contract Manufacturing 2,026 1,854 2,470 Total 2,098 2,215 2,527 Investor Presentatio
Slide 41: Product Category Wise Revenue Bifurcation
Product Category Wise Revenue Bifurcation In % FY22 FY23 FY24 7% 14% 7% 4% 4% 17% 17% 23% 50% 72% 72% 13% Tablet Ointments Capsules Other Products & Other Operating Revenue In ₹ Lakhs Products FY22 FY23 FY24 Tablet 1,505 1,107 1,597 Ointment 365 298 487 Capsules 88 498 29 Other operating Revenues 54
Slide 42: Stock Information
Stock Information As on 21-11-2024 As on 30-09-2024 NSE: MEDIORG Share Holding Pattern Share Price (₹ ) 52.95 Market Capitalization (₹Cr) 61.95 40% Promoter & Promoter Group No. of Shares Outstanding 1,17,00,000 Public Face Value (₹) 10.00 60% 52 Week High-Low (₹) 159.40 / 51.15 Share Performance Fr
Slide 43: SWOT Analysis
SWOT Analysis Strength Weakness o Good relations with established distributors o Dependency on buyers o Wide range of registered products o Lack of Brand Awareness o Wide range of products under registration o Lack of firm arrangements Opportunities Threats o Expanding new geographical markets o Flu
Slide 44: Investment Rationale
Investment Rationale Diverse Product Portfolio Strategic Market Expansion Contract Manufacturing Expertise The company boasts a broad range of Recently, the company initiated direct The company has established itself as a pharmaceutical products, including exports to new markets like Burundi and tru
Slide 45: Thank You
Thank You MEDICAMEN ORGANICS LIMITED 10, Community Center No. 2, Ashok Vihar, Phase-II Delhi - 110052 (India) Email: sale@mediorganics.in Phone: + 91 - 011-27430249 Website: www.medicamenorganics.com Kirin Advisors Private Limited 713-B, Lodha Supremus II, Wagle Estate, Thane West – 400 604. Email: